You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News items for the in vitro diagnostics industry for the week of Feb. 10, 2020.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.
News items for the in vitro diagnostics industry for the week of Jan. 27, 2020.
The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.
The company said preliminary revenues for full-year 2019 are expected to increase 66 percent year over year.
The AlloSeq cfDNA kit is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.